ESMO 2019: Delegates told refractory metastatic renal cell carcinoma is an unmet need with great growth potential
According to expert opinion, 20─30% of patients with stage I–III localised tumours will...
Trending menu:
-
![]()
ESMO 2019: Research questions whether high costs of new oncology treatments are associated with added clinical benefits
-
![]()
ESMO 2019: Final FLAURA results reinforce front-line approval of AstraZeneca’s Tagrisso
-
![]()
AstraZeneca’s Imfinzi falls at another hurdle in non-small cell lung cancer trial
-
![]()
Improved clinical efficacy found wanting in Phase III IMPALA trial
-
![Opdivo]()
Opdivo (Nivolumab) for the Treatment of Unresectable or Metastatic Melanoma
-
![]()
GSK’s Zejula meets primary goal in Phase III ovarian cancer trial
Latest Content
Lilly’s pegilodecakin fails in Phase III pancreatic cancer trial
Eli Lilly has reported that the Phase III SEQUOIA clinical trial of pegilodecakin failed to meet the primary endpoint of overall survival in patients with metastatic pancreatic cancer.
Replimune enrols first patient in Phase II CSCC study
Replimune Group has commenced patient enrolment in a Phase II clinical trial being conducted to assess its Immulytic product candidate RP1.
MorphoSys and I-Mab to expand multiple myeloma trials to China
MorphoSys and I-Mab Biopharma have announced plans to expand the ongoing Phase II and III multiple myeloma (MM) clinical trials to mainland China following clearances from the National Medical Products Administration (NMPA).
Signant Health offers eConsent support for oncology trial in UK
Clinical trial solutions provider Signant Health has agreed to provide electronic informed consent (eConsent) support for an oncology trial by the University of Bristol in the UK.
Seattle Genetics starts combination therapy trial in breast cancer
Seattle Genetics has commenced dosing in a Phase III clinical trial of its tucatinib drug in combination with Kadcyla (ado-trastuzumab emtansine) in HER2-positive (HER2+) breast cancer patients.
ESMO 2019: Delegates told refractory metastatic renal cell carcinoma is an unmet need with great growth potential
According to expert opinion, 20─30% of patients with stage I–III localised tumours will relapse after nephrectomy and progress to stage IV metastatic RCC, which requires systemic drug therapy.
Debiopharm begins enrolment in CATRIPCA trial
Debiopharm has started enrolling patients in its CATRIPCA Phase I clinical trial evaluating Debio 1143 in combination with Merck’s Keytruda for the treatment of cancer.
ESMO 2019: Research questions whether high costs of new oncology treatments are associated with added clinical benefits
Two studies presented at the European Society of Medical Oncology indicated that many new anti-cancer medicines added little clinical benefit for patients.
ESMO 2019: Final FLAURA results reinforce front-line approval of AstraZeneca’s Tagrisso
Final results from the Phase III FLAURA trial investigating AstraZeneca’s Tagrissofinal reinforce the therapy as the SOC for first-line treatment of patients with EGFRm advanced NSCLC, according to the study's author.
Chi-Med begins new trial for lymphoma treatment
Hutchison China MediTech (Chi-Med) has commenced a Phase I/Ib clinical trial for the treatment of relapsed or refractory lymphoma patients using its investigational drug candidate HMPL-523.
Close
Close
Close
Go Top
